A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Condition: Breast Neoplasms Interventions: Drug: Imlunestrant; Drug: Tamoxifen; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane Sponsor: Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Research | Study | Tamoxifen